# US 2024/0173342 A1 · Effects of lgm2605 on a primate model of asthma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0173342 A1
- Document ID: US20240173342A1
- Status: Published application
- Kind: A1
- Application number: 17/549,584
- Filed: 2021-12-13
- Published: 2024-05-30
- Earliest claimed: 2014-05-30
- Assignees: The Trustees of the University of Pennsylvania; The Regents of the University of California
- Applicants: The Trustees of the University of Pennsylvania; The Regents of the University of California
- Inventors: Melpo Christofidou-Solomidou; Angela Haczku
- Web page: https://patentgrep.com/patent/US20240173342A1

## CPC

- A61K 31/7032: attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 11/06: Antiasthmatics
- A61P 39/00: General protective or antinoxious agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.

## Claims

### Claim 1

A method for treating asthma in a human subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of chemically synthesized secoisolaricirecinol diglucoside (SDG).

### Claim 2 (depends on 1)

The method of claim 1, wherein the chemically synthesized SDG comprises a racemic mixture of the SDG.

### Claim 3 (depends on 1)

The method of claim 1, wherein administration of the chemically synthesized SDG alleviates or eliminates respiratory airway hyperactivity in the subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein the respiratory airway is an upper respiratory airway, a lower respiratory airway or a combination thereof.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein administration of the chemically synthesized SDG alleviates or eliminates bronchoalveolar lavage (BAL) inflammation in the subject, and wherein alleviation or elimination of the BAL inflammation comprises reducing BAL neutrophilia and eosinophilia.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the chemically synthesized SDG inhibits surfactant protein-D (SP-D) de-oligomerization.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the chemically synthesized SDG is administered in a dietary composition.

### Claim 11 (depends on 1)

The method of claim 1, wherein the chemically synthesized SDG is administered orally.

### Claim at position 12

-36. (canceled)

### Claim 37

A method for treating ozone-induced damage in a human subject who has been or will be exposed to a dose of ozone, the method comprising: orally administering to the subject a therapeutically effective amount of chemically synthesized SDG.

### Claim 38 (depends on 37)

The method of claim 37, wherein the chemically synthesized SDG comprises a racemic mixture of the SDG.

### Claim 39 (depends on 37)

The method of claim 37, wherein administration of the chemically synthesized SDG alleviates or eliminates airway hyperactivity in the subject.

### Claim 40 (depends on 37)

The method of claim 37, wherein the ozone-induced damage is airway hyperactivity, airway inflammation, oxidative stress of a airway or a combination thereof.

### Claim 41 (depends on 40)

The method of claim 40, wherein the airway is an upper airway, a lower airway or a combination thereof.

### Claim at position 18

-45. (canceled)

### Claim 46 (depends on 37)

The method of claim 37, wherein the chemically synthesized SDG inhibits surfactant protein-D (SP-D) de-oligomerization.

### Claim 47 (depends on 37)

The method of claim 37, wherein the chemically synthesized SDG is administered in a dietary composition.

### Claim 48

(canceled)

### Claim 49 (depends on 37)

The method of claim 37, wherein the chemically synthesized SDG is in a concentration about 1 nanomolar (nM) to about 1 molar (M).

### Claim 50 (depends on 49)

The method of claim 49, wherein the SDG concentration is about 25 μM to about 250 μM.

### Claim 51

(canceled)
